Drug
Nipocalimab clinical trials
Also written JNJ-80202135 and M281.
- studies test it
- 25
- open now
- 9
- in phase 3
- 10
- first study started
- 2016
Keep track of what changes. Save the nipocalimab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
- M281
- 13
Studies by the year they started
25 studies that test it; most in 2021 (6)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 3 |
| 2021 | 6 |
| 2022 | 4 |
| 2023 | 3 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 12
- Phase 3
- 10
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 25 · Other 0
Janssen Research & Development, LLC (22) · Momenta Pharmaceuticals, Inc. (3)
Often tested with
Tested in the same studies.
Etanercept (1) · Hydroxychloroquine (1) · Immunoglobulins, Intravenous (1)
Studies
Open first, then newest update. How each study uses nipocalimab is read from its arms, and is right about nine times in ten.
Testing it · 25
- A Study to Assess Nipocalimab Concentrations in Breast Milk of Healthy Lactating WomenRecruitingPhase 1Janssen Research & Development, LLCNCT07669077Written as Nipocalimab
- A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)RecruitingPhase 3Janssen Research & Development, LLCNCT05912517Written as Nipocalimab
- Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)RecruitingPhase 2/3Janssen Research & Development, LLCNCT05327114Written as Nipocalimab
- A Study of Nipocalimab in Reducing the Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)RecruitingPhase 3Janssen Research & Development, LLCNCT06449651Written as Nipocalimab
- A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)RecruitingPhase 3Janssen Research & Development, LLCNCT06533098Written as Nipocalimab
- Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia GravisRecruitingPhase 3Janssen Research & Development, LLCNCT07217587Written as Nipocalimab
- A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus ErythematosusRecruitingPhase 3Janssen Research & Development, LLCNCT07438496Written as Nipocalimab
- A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia GravisRecruitingPhase 2/3Janssen Research & Development, LLCNCT05265273Written as Nipocalimab
- A Study of Nipocalimab Administered to Adults With Generalized Myasthenia GravisRecruitingPhase 3Janssen Research & Development, LLCNCT04951622Written as Nipocalimab
- Nipocalimab in Moderate to Severe Sjogren's DiseaseActive, not recruitingPhase 3Janssen Research & Development, LLCNCT06741969Written as Nipocalimab
- A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory MyopathiesActive, not recruitingPhase 2Janssen Research & Development, LLCNCT05379634Written as Nipocalimab
- Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic AnemiaActive, not recruitingPhase 2/3Janssen Research & Development, LLCNCT04119050Written as M281
- A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Pregnant Women at High Risk for Early Onset Severe Hemolytic Disease of the Fetus and Newborn (HDFN)CompletedPhase 2Janssen Research & Development, LLCNCT03842189Written as M281
- A Study of Nipocalimab in Adult Participants With Active Lupus NephritisWithdrawnPhase 2Janssen Research & Development, LLCNCT04883619Written as Nipocalimab
- A Study of Nipocalimab in Adult Participants With Active Systemic Lupus ErythematosusCompletedPhase 2Janssen Research & Development, LLCNCT04882878Written as Nipocalimab
- A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS)CompletedPhase 2Janssen Research & Development, LLCNCT04968912Written as Nipocalimab
- A Study to Evaluate the Nipocalimab and Certolizumab Combination Therapy in Participants With Active Rheumatoid ArthritisCompletedPhase 2Janssen Research & Development, LLCNCT06028438Written as Nipocalimab
- A Proof-of-concept Study of the Efficacy and Safety of Nipocalimab in Participants With Active Rheumatoid ArthritisCompletedPhase 2Janssen Research & Development, LLCNCT04991753Written as Nipocalimab
- A Study on the Effect of Nipocalimab on Vaccine Responses in Healthy ParticipantsCompletedPhase 1Janssen Research & Development, LLCNCT05827874Written as Nipocalimab
- A Study of Nipocalimab With Co-administration of Etanercept or Hydroxychloroquine in Healthy ParticipantsCompletedPhase 1Janssen Research & Development, LLCNCT04973566Written as Nipocalimab
Codes
What other systems call nipocalimab · ClinicalTrials.gg INT002146
- MeSH (NLM) C000731839nipocalimabOne source NLM
- UNII (FDA) 87M90CV8NCNIPOCALIMABConfirmed FDA, NLM, Wikidata
- Wikidata Q130302151nipocalimabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C170891NipocalimabOne source FDA
- DrugBank DB16257One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000731839 | nipocalimab | One source NLM |
| UNII (FDA) | 87M90CV8NC | NIPOCALIMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q130302151 | nipocalimab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C170891 | Nipocalimab | One source FDA |
| DrugBank | DB16257 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.